| Date | Title | Description |
| 29.07.2024 | Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development | • Proceeds to support Phase 1 clinical trials for two proprietary programs, and to advance two additional programs to IND approval
• Company to expand R&D efforts to discover additional development candidates for rare endocrine diseases... |
| 26.07.2024 | Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical company | Dear shareholder,
Dear Madam, Dear Sir,
please find attached our press release.
Best regards
Ackermans & van Haaren
Attachment
Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics (press releas... |
| 26.07.2024 | Confo Therapeutics Raises EUR 60M in Series B Financing | Confo Therapeutics, a Ghent, Belgium-based clinical-stage company and innovator in the discovery of medicines targeting G-protein coupled receptors (GPCRs), raised EUR60M in Series B funding.
The round was led by Ackermans & van Haaren ... |
| 16.12.2021 | Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform | Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform |
| 30.11.2021 | Confo Therapeutics Enters Collaborative Agreement with Regeneron | Confo Therapeutics Enters Collaborative Agreement with Regeneron |
| 30.11.2021 | Confo Therapeutics Enters Collaborative Agreement with Regeneron | Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery. |
| 30.03.2021 | Confo Therapeutics awarded € 1 million VLAIO grant for pre-clinical development of CFTX-1554, an AT2R modulator for the treatment of neuropathic pain | Ghent, Belgium: 30 March 2021 – Confo Therapeutics announced today that it has been awarded a € 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development of CFTX-1554, Confo... |
| 15.10.2020 | Confo Therapeutics announces selection of first product candidate and initiation of pre-clinical development | Ghent, Belgium: 15 October 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain ... |
| 10.06.2020 | Confo Therapeutics expands Board with appointment of Rob Scott as Independent Director | Ghent, Belgium: 10 June 2020 – Confo Therapeutics today announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director. Dr Scott’s career spans 30 years of drug discovery a... |
| 03.06.2020 | Confo Therapeutics appoints Paolo Vicini as Chief Development Officer | New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates |
| 27.02.2020 | Confo Therapeutics to present at Cowen 40th Annual Health Care Conference | Ghent, Belgium: 27 February 2020 – Confo Therapeutics, a pioneering biopharma company, today announces that Cedric Ververken, CEO, will present at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020 at 3:00 p.m. ET in Bos... |
| 02.12.2019 | Confo Therapeutics reports grant of two key patents for ConfoBodies™ | Ghent, Belgium: 2 December 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been granted two key ConfoBodyTM patents derived from the patent estate known as the “Steyaert patents”. |
| 23.09.2019 | FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019 | Confo Therapeutics today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Confo Therapeutics i... |
| 23.09.2019 | FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019 | Ghent, Belgium: 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising ... |
| 03.07.2019 | Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds | Ghent, Belgium, and Dresden, Germany: 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). |
| 21.06.2019 | Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication | Confo Therapeutics today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical progr... |
| 20.06.2019 | Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication | Ghent, Belgium: 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years ... |
| 09.05.2019 | Term Sheet — Thursday, May 9 | UBER HYPE
The biggest IPO since Alibaba. The most anticipated Silicon Valley IPO since Facebook. The largest IPO of 2019.
Paid Content How can you protect what you can't see? From ExtraHop
Fortune’s Adam Lashinsky wrote the following in Dat... |
| 08.05.2019 | Daily funding roundup - May 8th, 2019 | Journey Meditation raised $2.4M; Data Gumbo landed $6M; Pearl closed $11M; HeyJobs secured $12M
Lora DiCarlo: Lora DiCarlo is the disruptive new brand known for engineering pleasure tech products. Lora DiCarlo has raised $2 million in fundi... |
| 08.05.2019 | Confo Therapeutics Raises €30M in Series A Financing | Confo Therapeutics, a Ghent, Belgium-based drug discovery company, completed a €30m ($33.4m) Series A financing.
The round was led by BioGeneration Ventures (BGV) and co-led by Wellington Partners, with participation from new investors Fund... |
| 07.05.2019 | Confo Therapeutics raises € 30 million in Series A financing | Ghent, Belgium: 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a € 30 million ($ 33.4 million) Series A financing. The investment was led by BioGeneration Ventures (BGV) and co-led by ... |
| 07.05.2019 | Wellington Partners co-leads €30 million Series A financing in Confo Therapeutics | Ghent, Belgium, 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The investment was co-led by BioGeneration Ventures (BGV) and Wellingto... |
| 07.05.2019 | Confo raises €30M series A round to target hard-to-drug GPCRs | Confo Therapeutics has raised €30 million ($34 million) to take compounds targeting difficult-to-drug GPCRs into clinical development. The series A round (PDF) sets Confo up to advance drugs derived from a novel way of stabilizing GPCRs and... |
| 07.05.2019 | Confo raises €30M series A round to target hard-to-drug GPCRs | Confo Therapeutics has raised €30 million ($34 million) to take compounds targeting difficult-to-drug GPCRs into clinical development. The series A round (PDF) sets Confo up to advance drugs derived from a novel way of stabilizing GPCRs and... |
| 28.02.2019 | Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine | Ghent, Belgium: 28 February 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan S... |
| 03.01.2019 | Confo Therapeutics announces exclusive, worldwide license agreement with VIB for Powerful Novel Structure Determination Technology | |
| 20.02.2018 | Confo Therapeutics is awarded a € 1 million grant to increase its screening capabilities | Ghent, Belgium: 20 February 2018 – Confo Therapeutics announced today that it has received a € 1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the dev... |
| 19.12.2017 | Confo Therapeutics enters into drug discovery collaboration with Roche | Ghent, Belgium: 19 December 2017 – Confo Therapeutics, an emerging drug discovery company, announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisati... |
| 26.09.2017 | Confo Therapeutics enters into drug discovery collaboration with Lundbeck | Ghent, Belgium: 26 September 2017 – Confo Therapeutics, an emerging drug discovery company, today announced that it has entered into a drug discovery collaboration with H. Lundbeck A/S, a global pharmaceutical company specializing in psychi... |
| 01.02.2017 | Confo Therapeutics is awarded € 2.6 million in non-dilutive funding for the discovery of new fibrosis treatments and for expanding the use of its unique Confo® technology | Ghent, Belgium: 1 February 2017 – Confo Therapeutics, an emerging drug discovery company, today announced that it has received a €1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). Confo Therapeutics will use the gra... |
| 15.12.2016 | Confo Therapeutics to appoint John Berriman as Chairman of the Board | Brussels, Belgium: 15 December 2016 – Confo Therapeutics, an emerging drug discovery company, today announced the appointment of John Edward Berriman as non-executive director and chairman of the board of directors, starting December 21. |
| - | Confo Therapeutics | “Confo Therapeutics – Stabilize. Target. Discover. Transform.” |
